Financial reports
20-F
2023 FY
Annual report (foreign)
28 Mar 24
20-F
2022 FY
Annual report (foreign)
23 Mar 23
20-F
2021 FY
Annual report (foreign)
31 Mar 22
20-F/A
2020 FY
Annual report (foreign) (amended)
21 Apr 21
20-F
2020 FY
Annual report (foreign)
15 Apr 21
20-F
2019 FY
Annual report (foreign)
28 Apr 20
20-F
2018 FY
Annual report (foreign)
27 Mar 19
20-F
2017 FY
Annual report (foreign)
20 Mar 18
20-F
2016 FY
Annual report (foreign)
30 Mar 17
20-F
2015 FY
Annual report (foreign)
30 Mar 16
Current reports
6-K
Affimed Reports 2023 Financial Results and Operational Progress
28 Mar 24
6-K
Current report (foreign)
11 Mar 24
6-K
Affimed Announces 1-for-10 Reverse Stock Split
6 Mar 24
6-K
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype
8 Jan 24
6-K
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
8 Jan 24
6-K
Affimed Announces Positive Data for AFM24 in Combination with the PD-L1
11 Dec 23
6-K
Current report (foreign)
30 Nov 23
6-K
Unaudited consolidated interim statements of comprehensive loss
14 Nov 23
6-K
Affimed Announces Listing Transfer to NASDAQ Capital Markets
4 Oct 23
6-K
Unaudited consolidated interim statements of comprehensive loss
10 Aug 23
Registration and prospectus
S-8
Registration of securities for employees
23 Mar 23
424B5
Prospectus supplement for primary offering
23 Mar 23
424B5
Prospectus supplement for primary offering
14 Apr 22
424B5
Prospectus supplement for primary offering
12 Apr 22
POS AM
Prospectus update (post-effective amendment)
31 Mar 22
POSASR
Automatic shelf registration (post-effective amendment)
31 Mar 22
F-3ASR
Automatic shelf registration (foreign)
10 Nov 21
424B5
Prospectus supplement for primary offering
14 Jan 21
424B5
Prospectus supplement for primary offering
13 Jan 21
F-3
Shelf registration (foreign)
23 Dec 20
Proxies
No filings
Other
EFFECT
Notice of effectiveness
7 Apr 22
EFFECT
Notice of effectiveness
31 Dec 20
CORRESP
Correspondence with SEC
30 Dec 20
UPLOAD
Letter from SEC
29 Dec 20
EFFECT
Notice of effectiveness
8 Nov 18
UPLOAD
Letter from SEC
6 Nov 18
CORRESP
Correspondence with SEC
5 Nov 18
CT ORDER
Confidential treatment order
17 Sep 18
EFFECT
Notice of effectiveness
23 Oct 15
CORRESP
Correspondence with SEC
22 Oct 15
Ownership
SC 13G/A
Ridgeback Capital Investments L.P.
14 Feb 24
SC 13G/A
683 Capital Management, LLC
13 Feb 24
SC 13G/A
BlackRock Inc.
7 Jul 23
SC 13G/A
Ridgeback Capital Investments L.P.
14 Feb 23
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 23
SC 13G/A
683 Capital Management, LLC
14 Feb 23
SC 13G/A
Ridgeback Capital Investments L.P.
14 Feb 23
SC 13G
BlackRock Inc.
3 Feb 23
SC 13G
BlackRock Inc.
9 May 22
SC 13G
Gilde Healthcare Holding B.V.
21 Apr 22